Vitamin D3 for Life

Live Enlightened

Article

Pathophysiological consequences of altered enzyme activity: Full Study Summary

Previous related pageMagnesium Status and Functional Vitamin D Response: Study SummaryNext related pagePathophysiological consequences of altered enzyme activity: Study Summary
Study at a glance

How can faults in vitamin D processing affect calcium and phosphate balance?

This review explains how faults in vitamin D processing can disturb calcium and phosphate balance. It combines evidence from human genetic disorders, animal experiments and laboratory cell studies. Two enzymes, proteins that help chemical reactions occur, are central: CYP27B1 helps make active vitamin D, while CYP24A1 helps process vitamin D compounds for removal.

What happens when the body cannot make or remove active vitamin D properly?

Severe loss of CYP27B1 can prevent enough active vitamin D being made and cause rickets, in which growing bones do not harden properly. Loss of CYP24A1 can prevent normal removal, leading to high blood calcium and kidney complications. These are opposite faults affecting the same mineral-control system. Kidney disease can also reduce activation through several changes without an inherited enzyme defect.

Can too much active vitamin D be produced?

Yes. In certain diseases, including sarcoidosis and tuberculosis, immune cells outside the kidneys can make enough active vitamin D to contribute to high blood calcium. This is excessive production, rather than failed removal. Hormones also adjust activation and breakdown in response to changing mineral levels. A blood result therefore reflects both the original problem and the body’s response to it.

What remains uncertain about faults in vitamin D control?

Some ways the body controls vitamin D are not fully understood. Studies disagree about how the hormone calcitonin affects CYP24A1, and the ways calcium and phosphate influence activation are not fully explained. Results from different experimental models must keep their limits. Severe genetic disorders do not show that enzyme faults commonly cause vague symptoms, or that every tissue normally supplies large amounts of active vitamin D to the blood.

Read the full article below ↓

Disorders of CYP27B1 and CYP24A1 illustrate a useful principle in vitamin D physiology: similar disturbances of calcium and phosphate balance can arise from opposite biochemical failures. CYP27B1 loss limits the formation of calcitriol; CYP24A1 loss limits the inactivation of vitamin D metabolites; and dysregulated extra-renal CYP27B1 can produce too much calcitriol in defined inflammatory or granulomatous settings. Young and colleagues place these disease mechanisms within the normal proximal-tubule feedback network, showing how PTH, calcitriol, FGF23, calcitonin, calcium and phosphate alter the balance between activation and catabolism.

Why the proximal tubule is central to active vitamin D control

Most circulating 25(OH)D is bound to vitamin-D-binding protein. Filtered complexes can be reclaimed by proximal tubular cells through megalin: and cubilin-dependent uptake, allowing 25(OH)D to reach intracellular metabolism rather than simply being lost in urine. Within the cell, mitochondrial CYP27B1 converts 25(OH)D to calcitriol, while mitochondrial CYP24A1 promotes the further metabolism of 25(OH)D and calcitriol.

That arrangement makes the proximal tubule more than a passive site of conversion. The broader Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1) overview places these opposing reactions within the full enzyme pathway. It integrates substrate delivery with endocrine signals. The kidney is normally the principal regulated source of circulating calcitriol, so changes in renal CYP27B1 and CYP24A1 can alter systemic mineral homeostasis. Extra-renal expression becomes important for different reasons, particularly when local production becomes dysregulated in disease.

CYP27B1 loss causes an activation defect even when precursor is present

Pathogenic CYP27B1 loss-of-function causes vitamin-D-dependent rickets type 1A, also known as vitamin D hydroxylation-deficient rickets type IA. The biochemical block is downstream of 25(OH)D formation. A patient can therefore have vitamin D precursor available but still be unable to generate enough calcitriol.

The resulting phenotype includes hypocalcaemia, hypophosphataemia, secondary hyperparathyroidism and defective skeletal mineralisation with rickets. The review also notes a founder effect that has made the disorder unusually frequent in a French-Canadian population.

The disease is mechanistically informative because calcitriol treatment can bypass the missing activation step. This distinguishes CYP27B1 deficiency from ordinary low vitamin D substrate: when the enzyme itself is severely impaired, providing more precursor is not equivalent to replacing the active hormone that cannot be made efficiently.

Chronic kidney disease can also reduce calcitriol production, but through a broader acquired mechanism. Loss of functioning renal mass, altered substrate handling and endocrine changes (including high FGF23) reduce activation capacity without requiring a CYP27B1 mutation. Genetic enzyme loss and kidney failure therefore converge on low calcitriol through different upstream causes.

CYP24A1 loss causes a degradation defect

CYP24A1 deficiency shifts physiology in the opposite direction. Instead of failing to produce active hormone, the body fails to metabolise vitamin D compounds normally. Pathogenic CYP24A1 variants can cause idiopathic infantile hypercalcaemia and can also present with hypercalcaemia, hypercalciuria, nephrocalcinosis or nephrolithiasis.

The phenotype varies. Severe biallelic loss can present early, while other genotypes or environmental conditions may produce later or less dramatic disease. The important point is not that every variant causes the same syndrome, but that impaired catabolism can prolong vitamin D metabolite exposure enough to disturb calcium handling.

This makes CYP24A1 disease a useful counterpoint to CYP27B1 deficiency. Vitamin D Clearance and Degradation develops the physiology of impaired or increased catabolism. One disorder reflects too little activation; the other reflects too little inactivation. Both disturb the same mineral system, but they demand opposite mechanistic explanations.

Dysregulated extra-renal CYP27B1 can produce excessive calcitriol

A third pathophysiological route is excessive production outside the kidney. Activated macrophages can express substantial CYP27B1 activity in granulomatous disease. In settings such as sarcoidosis and tuberculosis, extra-renal conversion of 25(OH)D to calcitriol can become sufficient to contribute to systemic hypercalcaemia.

Related inflammatory and lymphomatous contexts can produce a similar pattern. The important distinction is that this is not CYP24A1 failure. It is excessive synthesis in cells operating outside the usual renal endocrine programme.

The disease mechanism also sets a boundary on normal physiology. Tissue-Specific Vitamin D Metabolism explains why renal and extra-renal production have different physiological consequences. Extra-renal CYP27B1 often supports local signalling without dominating circulating calcitriol. Granulomatous hypercalcaemia shows what can happen when that local capacity becomes dysregulated; it should not be used to imply that every CYP27B1-positive tissue is normally a major endocrine source.

PTH increases calcitriol availability through both sides of the enzyme pair

Low extracellular calcium stimulates parathyroid hormone secretion. In proximal tubular cells, PTH signals through PTHR1 and G-protein pathways, with cAMP/PKA and CREB among the important downstream components. Promoter studies discussed in the review also implicate transcription factors including NR4A2/Nurr1 and C/EBPβ in CYP27B1 regulation.

PTH raises calcitriol availability not only by stimulating CYP27B1 but also by weakening the catabolic arm. The review reports that PTH reduces CYP24A1 mRNA half-life by approximately fourfold. That post-transcriptional effect means that the same hormone can favour active vitamin D by increasing synthesis and reducing persistence of the transcript that supports catabolism.

Parathyroidectomy experiments reinforce the physiological importance of this pathway. Animals deprived of parathyroid input fail to mount the normal calcitriol response to low calcium until PTH or parathyroid extract is restored. The result demonstrates endocrine integration rather than a promoter effect that exists only in isolated cells.

Calcitriol feeds back through VDR to limit further production

Calcitriol closes the loop. Liganded VDR forms a transcriptional complex with RXR and regulates vitamin-D-response elements. In kidney, calcitriol suppresses CYP27B1 while inducing CYP24A1, reducing further hormone production and increasing metabolic inactivation.

VDR-null models lose normal feedback and develop abnormal calcitriol regulation, supporting the physiological importance of receptor-mediated control. Calcitriol also suppresses PTH transcription, providing an indirect route by which high active-hormone levels reduce one of the major stimulatory signals for CYP27B1.

The result is layered negative feedback. Active hormone acts directly on the renal enzymes and indirectly through the parathyroid axis. That is why the CYP27B1/CYP24A1 balance cannot be understood as two independent gene-expression readouts.

This feedback also changes how laboratory measurements should be interpreted in disease. A high or low calcitriol concentration is not a direct readout of one enzyme in isolation: it reflects substrate delivery, CYP27B1-dependent synthesis, CYP24A1-dependent metabolism and the compensatory hormones that respond to the disturbance. The same primary lesion can therefore produce different measured patterns at different stages of disease or treatment. Conversely, similar calcium or phosphate abnormalities can arise from defects at different points in the pathway. The enzyme phenotype has to be understood together with PTH, FGF23, renal function and the direction of calcitriol change rather than inferred from a single concentration. Vitamin D Metabolism at the Cellular Level follows the intracellular handling that contributes to those measured metabolite patterns.

FGF23 suppresses activation and promotes the catabolic direction

FGF23 is produced mainly by bone cells and signals in kidney through FGF receptors in association with klotho. MAPK/ERK signalling is an important downstream component. The review describes promoter experiments in which FGF23 suppresses CYP27B1 activity and ERK1/2 inhibition interferes with that suppression.

FGF23-null mice provide quantitative support. Renal CYP27B1 promoter activity was approximately threefold higher than in wild-type animals, consistent with loss of an inhibitory signal. At the same time, renal Cyp24a1 mRNA was about 63% lower, showing that FGF23 normally pushes metabolism toward the catabolic side as well as suppressing activation.

The exact molecular route from FGF23 signalling to every component of CYP24A1 regulation is less completely resolved than the physiological direction. That difference in certainty is important: the evidence strongly supports reciprocal effects on the enzyme system even where the full transcriptional mechanism remains incomplete.

In chronic kidney disease, rising FGF23 can therefore contribute to declining calcitriol by reducing CYP27B1 drive and favouring CYP24A1. It is one part of a broader renal disease process rather than a complete explanation on its own.

Calcitonin regulation is real but not resolved into one universal CYP24A1 response

Calcitonin generally stimulates CYP27B1. Experimental work implicates signalling through PKC and C/EBPβ, and the hormone may become especially relevant when calcium is high and PTH is suppressed.

Its effect on CYP24A1 is more complicated. In thyroparathyroidectomised rats maintained on a low-calcium diet, loss of endogenous hormones was associated with increased Cyp24a1 expression and calcitonin administration reduced the transcript. In contrast, calcitonin-receptor-transfected HEK-293 cells showed induction of CYP24A1. In that engineered-cell system, inhibiting PKA or PKC reduced the calcitonin-induced response by about 60%.

The two findings point in opposite directions. Differences in species, calcium and calcitriol status, tissue context and receptor engineering may help explain the discrepancy, but the review does not resolve it. The appropriate conclusion is that calcitonin participates in vitamin D enzyme regulation while its CYP24A1 effect remains context dependent and incompletely defined.

Phosphate changes calcitriol production, but the sensing pathway is still incomplete

Low phosphate is associated with increased CYP27B1 expression and increased calcitriol synthesis. Experimental phosphate depletion can enhance calcitriol production by roughly threefold. The response can occur even when PTH is not the main driver, indicating that phosphate status reaches the activation system through additional signals.

The sensing mechanism is less certain than the physiological observation. Hypophysectomy can abolish the response to phosphate depletion, suggesting that pituitary factors contribute. Growth hormone has been proposed as one candidate, but the pathway is not fully mapped.

This is a useful example of different levels of evidence strength. The direction of the physiological response is well supported, while the molecular relay between low phosphate and renal CYP27B1 remains incomplete.

Calcium can oppose CYP27B1 independently of ordinary PTH feedback

Experimental evidence also supports a calcium-sensitive component of CYP27B1 regulation. In thyroparathyroidectomised animals, calcium infusion suppresses renal Cyp27b1. When calcium and PTH are supplied together, higher calcium can blunt the stimulatory effect of PTH; preventing the calcium rise permits a stronger PTH response.

The calcium-sensing receptor and downstream MAPK/PKC pathways are plausible components, and promoter studies support calcium sensitivity. Even so, the complete molecular path from extracellular calcium sensing to CYP27B1 transcription has not been established.

Physiology therefore appears to combine classical endocrine feedback with local sensing. PTH carries information about calcium need, while calcium itself can influence the renal activation machinery.

Opposite enzyme defects converge on the same mineral-homeostasis network

The disease examples become easier to interpret when placed back into this feedback system. CYP27B1 loss reduces calcitriol production. CYP24A1 loss reduces vitamin D metabolite clearance. Granulomatous macrophage CYP27B1 increases calcitriol production outside ordinary renal control. Chronic kidney disease reduces renal activation capacity while changing hormones such as FGF23 and PTH.

Each initiating defect then provokes compensation. Calcium, phosphate, PTH, FGF23 and calcitriol concentrations change and feed back on both enzymes. A laboratory phenotype is therefore the combined result of the primary lesion and the body’s attempt to restore mineral balance.

That complexity is one reason severe monogenic disorders should not be used as a template for explaining common nonspecific symptoms. The review supports well-defined pathophysiological mechanisms; it does not show that clinically important CYP27B1 or CYP24A1 dysfunction is a common hidden cause of fatigue, pain or other broad symptoms.

What this review establishes and where uncertainty remains

Young and colleagues provide a focused narrative review rather than a new patient cohort. Their account integrates human genetic disorders, animal physiology, promoter experiments and cell-signalling studies. The pathophysiological directions are therefore supported at a synthesis level, while individual numerical findings retain the boundaries of the models from which they came.

The strongest conclusions are clear. CYP27B1 loss can cause activation failure and rickets; CYP24A1 loss can cause impaired catabolism and hypercalcaemic renal phenotypes; dysregulated extra-renal CYP27B1 can drive hypercalcaemia in granulomatous disease; and the renal enzyme pair is regulated reciprocally by major endocrine signals.

Some regulatory details remain less settled. Calcitonin has conflicting reported effects on CYP24A1, the mechanism of phosphate sensing is incomplete, and calcium-sensitive CYP27B1 regulation is not fully mapped from receptor to transcription. Preserving these uncertainties is essential because they distinguish established physiological direction from an unfinished molecular mechanism.

Primary source and publication details

Young K, Beggs MR, Grimbly C, Alexander RT. Regulation of 1 and 24 hydroxylation of vitamin D metabolites in the proximal tubule. Experimental Biology and Medicine (Maywood). 2022;247(13):1103 to 1111. PMID 35482362; PMCID PMC9335508; DOI 10.1177/15353702221091982.

Read the full Young et al. review.

The Study Summary provides a faster route through the same mechanisms.

Related reading

Original sources